Tempus AI (TEM) CEO Lefkofsky Eric P Sells $16M of Stock
Key Points
- Tempus AI, Inc. CEO and Chairman Eric P. Lefkofsky sold 200,000 shares of TEM stock for about $16.1 million on September 17, 2026, according to a Form 4 filing with the SEC.
- The health technology company trades with a market cap near $12.8 billion, trailing-twelve-month revenue of $1.43 billion, and holds an upcoming earnings report scheduled for November 2, 2026.
- Analyst coverage shows a consensus buy rating with a mean price target of $74.94, following multiple recent updates from firms including Rothschild & Co, UBS, and Goldman Sachs.
Since the trade, $TEM is up 2.3% after 1 week, down 19.9% after 1 month and down 19.9% to date (from the $80.36 close on Sep 17, 2026).
Get Tempus AI text alerts
We text you when insiders, Congress, analysts or big funds move on $TEM.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Tempus AI, Inc. alert may contain errors. Disclosures
Tempus AI, Inc. CEO and Chairman Eric P. Lefkofsky sold 200,000 shares of the healthcare technology company on September 17, 2026. The transaction was revealed in a Form 4 filed with the Securities and Exchange Commission.
TEM
Tempus AI, Inc.
Inside Eric P. Lefkofsky's TEM Trade
Lefkofsky executed the sale of 200,000 shares at an average price of $80.57, bringing the total value of the transaction to $16,113,800. The trade was carried out pursuant to a pre-arranged Rule 10b5-1 trading plan. On the day of the transaction, TEM shares closed at $80.36.
Other Institutional Activity in Tempus AI
Large investment firms have adjusted their positions in TEM recently. ARK Investment Management, LLC grew its holdings by 415,048 shares, ending with 10,022,634 shares worth about $644.9 million. BAILLIE GIFFORD & CO reduced its stake by 459,284 shares, holding 8,190,133 shares valued at about $527.0 million. Softbank Group Corporation kept its holding steady at 5,405,406 shares worth about $347.8 million. Sumitomo Mitsui Trust Group, Inc. cut its position by 237,070 shares, finishing with 4,089,029 shares valued at about $263.1 million. Amova Asset Management Americas Inc also trimmed its stake by 237,070 shares, holding 4,089,029 shares worth about $263.1 million.
Tempus AI, Inc. Stock Down 1.4%
Shares recently traded around $63.83 as of October 16, 2026, which is below the closing price on the day of the CEO's sale. The stock has moved between a 52-week low of $40.77 and a 52-week high of $96.29.
Recent Earnings
The company reported trailing-twelve-month revenue of $1.43 billion and earnings of -$1.44 per share. Its next quarterly financial update is scheduled for November 2, 2026.
Insider Buying and Selling at Tempus AI, Inc.
Earlier in September, other insiders completed transactions, including director David R Epstein selling 250 shares and director Jennifer A. Ph.D. Doudna selling 676 shares on September 1. Officer Ryan Fukushima sold 30,846 shares on the same date, while EVP and Chief Legal Officer Andrew Polovin sold 2,951 shares on September 17.
Analysts Set New Price Targets
Analyst coverage has seen several updates in recent weeks. On September 8, 2026, Rothschild & Co initiated coverage with a Neutral rating and a $67.00 price target. Roth Capital also initiated coverage on September 8 with a Neutral rating and a $67.00 target. UBS followed on September 9 with a Neutral rating and a $70.00 target. HC Wainwright & Co. maintained a Buy rating on September 11 while raising its target to $66.00 from $56.00. Later, on September 21, Goldman Sachs initiated coverage with a Neutral rating and a $75.00 target. Overall, the stock carries a consensus buy recommendation and a mean price target of $74.94 across 18 analyst opinions.
About Tempus AI
Tempus AI operates a healthcare technology platform in the United States that connects clinical data, laboratory diagnostics, and analytics for physicians and researchers. The company focuses on integrating multimodal data to assist healthcare providers with diagnostic tests and clinical applications.
Bottom Line
Investors will look ahead to the company's earnings release on November 2, 2026, for updates on revenue growth and profitability. Monitoring future Form 4 filings will show whether other executives continue executing planned sales.
Related Filing Alerts
Source: Lefkofsky Eric P's Form 4 filing on $TEM (Sep 17, 2026). Written by software, not financial advice. How we make alerts